Trial Profile

Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Corticotropin (Primary)
Indications Dermatomyositis; Myositis; Polymyositis
Focus Proof of concept; Therapeutic Use

Most Recent Events

06 Nov 2023 Results assessing efficacy and safety of RCI for treating refractory cutaneous DM published in the Rheumatology
11 Mar 2020 Results (N=8), 6 months follow up results, published in the Rheumatology
24 Oct 2018 Long Term Follow-up Results of myositis patients after 6 months of treatment (n=10) presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com